Published in J Biol Chem on June 15, 2010
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58
Human pathogens and the host cell SUMOylation system. J Virol (2011) 1.31
Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2012) 1.05
Deubiquitylating enzymes and DNA damage response pathways. Cell Biochem Biophys (2013) 1.03
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci (2015) 0.95
Two distinct sites in Nup153 mediate interaction with the SUMO proteases SENP1 and SENP2. Nucleus (2012) 0.89
Starting and stopping SUMOylation. What regulates the regulator? Chromosoma (2013) 0.88
Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci (2015) 0.88
Advances in the development of SUMO specific protease (SENP) inhibitors. Comput Struct Biotechnol J (2015) 0.88
Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol (2013) 0.87
Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci (2012) 0.86
SUMO-specific proteases/isopeptidases: SENPs and beyond. Genome Biol (2014) 0.85
Transcriptional repression of estrogen receptor α signaling by SENP2 in breast cancer cells. Mol Endocrinol (2013) 0.82
Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding. Nat Commun (2014) 0.81
Assays for investigating deSUMOylation enzymes. Curr Protoc Mol Biol (2012) 0.80
Sentrin/SUMO specific proteases as novel tissue-selective modulators of vitamin D receptor-mediated signaling. PLoS One (2014) 0.80
Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications. Int J Mol Sci (2015) 0.79
Inhibition of SENP1 induces radiosensitization in lung cancer cells. Exp Ther Med (2013) 0.78
MUMAL: multivariate analysis in shotgun proteomics using machine learning techniques. BMC Genomics (2012) 0.77
15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells. Cancer Med (2014) 0.77
SENP1-modulated sumoylation regulates retinoblastoma protein (RB) and Lamin A/C interaction and stabilization. Oncogene (2016) 0.76
Genetic Polymorphism of SUMO-Specific Cysteine Proteases - SENP1 and SENP2 in Breast Cancer. Pathol Oncol Res (2016) 0.75
Allosteric activation of SENP1 by SUMO1 β-grasp domain involves a dock-and-coalesce mechanism. Elife (2016) 0.75
SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. Oncotarget (2016) 0.75
SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation. Int J Mol Sci (2017) 0.75
Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget (2016) 0.75
Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia. Oncol Lett (2016) 0.75
SENP1 Is a Crucial Regulator for Cell Senescence through DeSUMOylation of Bmi1. Sci Rep (2016) 0.75
Downregulation of SENP1 inhibits cell proliferation, migration and promotes apoptosis in human glioma cells. Oncol Lett (2016) 0.75
SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases. Proteomics (2014) 0.75
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer. Biomolecules (2012) 0.75
Novel SUMO-Protease SENP7S Regulates β-catenin Signaling and Mammary Epithelial Cell Transformation. Sci Rep (2017) 0.75
SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget (2016) 0.75
High-altitude adaptation in humans: from genomics to integrative physiology. J Mol Med (Berl) (2017) 0.75
Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol (2007) 11.48
SUMO: a history of modification. Mol Cell (2005) 10.40
The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A (2002) 5.98
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
Modification in reverse: the SUMO proteases. Trends Biochem Sci (2007) 3.84
Ubiquitin-like proteins: new wines in new bottles. Gene (2000) 3.46
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res (2006) 2.46
Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. J Biol Chem (1997) 1.86
Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med (2001) 1.82
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol (2001) 1.71
D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res (1999) 1.67
Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res (2001) 1.66
Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev (2004) 1.60
Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A (2001) 1.43
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem (2007) 1.41
Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res (2002) 1.39
Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab (2004) 1.35
Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol (2006) 1.32
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate (2000) 1.21
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol (2007) 1.15
A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene (2005) 1.12
Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate (2003) 1.12
Two androgen response elements in the androgen receptor coding region are required for cell-specific up-regulation of receptor messenger RNA. Mol Endocrinol (1996) 1.08
Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene (1998) 1.06
The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res (2006) 1.00
Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radic Res (2007) 0.93
Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann N Y Acad Sci (2002) 0.92
Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate (1996) 0.88
Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol (1999) 0.87
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86
A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci U S A (2004) 2.74
SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell (2010) 2.52
Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation (2003) 2.28
Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem (2006) 2.15
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature (2012) 2.11
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab (2005) 1.99
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci U S A (2011) 1.94
Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol (2003) 1.88
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun (2005) 1.68
Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol (2005) 1.67
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol (2007) 1.62
Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat Cell Biol (2006) 1.62
Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. Exp Cell Res (2004) 1.59
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun (2012) 1.58
Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res (2008) 1.56
Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation (2004) 1.55
Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol Cell (2010) 1.50
Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation (2004) 1.46
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res (2010) 1.46
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A (2013) 1.43
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer (2010) 1.42
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J (2009) 1.41
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem (2007) 1.41
Relaxin promotes prostate cancer progression. Clin Cancer Res (2007) 1.34
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity (2006) 1.33
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res (2008) 1.30
NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol (2006) 1.30
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep (2008) 1.27
Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J Virol (2005) 1.26
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res (2010) 1.26
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26
RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res (2004) 1.25
Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med (2008) 1.24
Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res (2006) 1.24
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res (2008) 1.22
Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res (2011) 1.21
Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis. J Cell Sci (2003) 1.21
Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci (2003) 1.20
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell (2012) 1.16
SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem (2010) 1.16
Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J Biol Chem (2003) 1.15
Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer (2008) 1.15
FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res (2013) 1.14
Modification of nonstructural protein 1 of influenza A virus by SUMO1. J Virol (2010) 1.13
Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol (2002) 1.12
Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells. J Clin Invest (2015) 1.12
SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 1.11
Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. EMBO J (2010) 1.11
NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell (2011) 1.09
Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by alpha 4 beta 1 integrin/vascular cell adhesion molecule-1 interaction. Circ Res (2007) 1.09
Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol (2008) 1.08
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol (2010) 1.07
A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res (2007) 1.07
INPP4B: the new kid on the PI3K block. Oncotarget (2011) 1.07
Nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation. Proc Natl Acad Sci U S A (2011) 1.06
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res (2004) 1.06
Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J Biol Chem (2010) 1.06
Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2012) 1.05
Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol (2010) 1.04
Biology and clinical management of prostate cancer bone metastasis. Front Biosci (2007) 1.04
Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol (2004) 1.03
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol (2005) 1.03
SUMOylation and de-SUMOylation in response to DNA damage. FEBS Lett (2011) 1.03
CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation. J Clin Invest (2004) 1.02
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res (2013) 1.01
Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res (2007) 1.00
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res (2011) 1.00
C-reactive protein: structure affects function. Circulation (2004) 1.00
16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res (2007) 1.00
The pleiotropic effects of statins. Curr Opin Cardiol (2005) 0.99